Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases affecting bone health and blood vessel function, has announced its upcoming participation in two major investor conferences. Doug Treco, Ph.D., CEO and Chairman, will present at the Stifel 2024 Healthcare Conference on November 18 (3:35-4:05pm ET) and the Jefferies London Healthcare Conference on November 20 (2:30-2:55pm GMT / 9:30-9:55am ET). Live webcasts will be available through Inozyme's website's Investor Relations section, with replays accessible for a time.
Inozyme Pharma (Nasdaq: INZY), un'azienda biofarmaceutica in fase clinica concentrata su malattie rare che influenzano la salute ossea e la funzione dei vasi sanguigni, ha annunciato la sua partecipazione imminente a due importanti conferenze per investitori. Doug Treco, Ph.D., CEO e Presidente, presenterà alla Stifel 2024 Healthcare Conference il 18 novembre (15:35-16:05 ET) e alla Jefferies London Healthcare Conference il 20 novembre (14:30-14:55 GMT / 9:30-9:55 ET). Saranno disponibili webcast in diretta attraverso la sezione Relazioni con gli Investitori del sito web di Inozyme, con repliche accessibili per un certo periodo.
Inozyme Pharma (Nasdaq: INZY), una empresa biofarmacéutica en etapa clínica centrada en enfermedades raras que afectan la salud ósea y la función de los vasos sanguíneos, ha anunciado su próxima participación en dos importantes conferencias para inversores. Doug Treco, Ph.D., CEO y Presidente, presentará en la Stifel 2024 Healthcare Conference el 18 de noviembre (3:35-4:05 p.m. ET) y en la Jefferies London Healthcare Conference el 20 de noviembre (2:30-2:55 p.m. GMT / 9:30-9:55 a.m. ET). Se podrán ver webcasts en vivo a través de la sección de Relaciones con Inversores del sitio web de Inozyme, con repeticiones accesibles por un tiempo.
이노자임 제약 (Nasdaq: INZY)은 뼈 건강과 혈관 기능에 영향을 미치는 희귀 질환에 초점을 맞춘 임상 단계의 생명공학 회사로, 두 가지 주요 투자자 회의에 참가기를 발표했습니다. 닥 드 트레코 박사, CEO이자 회장은 11월 18일 (오후 3:35-4:05 ET) 스티펠 2024 헬스케어 컨퍼런스와 11월 20일 (오후 2:30-2:55 GMT / 오전 9:30-9:55 ET) 제퍼리스 런던 헬스케어 컨퍼런스에서 발표할 예정입니다. 이노자임 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트가 제공되며, 특정 기간 동안 다시 볼 수 있습니다.
Inozyme Pharma (Nasdaq: INZY), une société biopharmaceutique en phase clinique axée sur les maladies rares affectant la santé osseuse et la fonction vasculaire, a annoncé sa prochaine participation à deux grandes conférences pour investisseurs. Doug Treco, Ph.D., PDG et président, présentera à la Stifel 2024 Healthcare Conference le 18 novembre (15h35-16h05 ET) et à la Jefferies London Healthcare Conference le 20 novembre (14h30-14h55 GMT / 9h30-9h55 ET). Des webcasts en direct seront disponibles via la section Relations avec les investisseurs du site web d'Inozyme, avec des rediffusions accessibles pendant un certain temps.
Inozyme Pharma (Nasdaq: INZY), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten konzentriert, die die Knochengesundheit und die Funktion der Blutgefäße betreffen, hat seine bevorstehende Teilnahme an zwei großen Investorenkonferenzen angekündigt. Doug Treco, Ph.D., CEO und Vorsitzender, wird am 18. November (15:35-16:05 Uhr ET) auf der Stifel 2024 Healthcare Conference und am 20. November (14:30-14:55 Uhr GMT / 9:30-9:55 Uhr ET) auf der Jefferies London Healthcare Conference präsentieren. Live-Webcasts werden über die Website von Inozyme im Bereich Investor Relations verfügbar sein, mit Wiederholungen, die für eine gewisse Zeit zugänglich sind.
- None.
- None.
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced Doug Treco, Ph.D., CEO and Chairman of Inozyme, will present at the following investor conferences:
- The Stifel 2024 Healthcare Conference. The presentation will take place on Monday, November 18 from 3:35-4:05pm ET.
- The Jefferies London Healthcare Conference. The presentation will take place on Wednesday, November 20 from 2:30-2:55pm GMT / 9:30-9:55am ET.
A live webcast of the presentations can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the events will also be available for a limited time.
About Inozyme Pharma
Inozyme Pharma is a pioneering clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics for rare diseases that affect bone health and blood vessel function. We are experts in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi), which regulates mineralization, and adenosine, which controls intimal proliferation (the overgrowth of smooth muscle cells inside blood vessels). Disruptions in this pathway impact the levels of these molecules, leading to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).
Our lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, addressing the significant morbidity and mortality in these devastating diseases.
For more information, please visit https://www.inozyme.com/ or follow Inozyme on LinkedIn, X, and Facebook.
Contacts
Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com
Media:
Biongage Communications
Todd Cooper
(617) 840-1637
todd@biongage.com
FAQ
When is Inozyme Pharma (INZY) presenting at the Stifel 2024 Healthcare Conference?
What time is Inozyme Pharma's (INZY) presentation at the Jefferies London Healthcare Conference?
How can investors watch Inozyme Pharma's (INZY) investor conference presentations?
Which investor conferences is Inozyme Pharma (INZY) attending in November 2024?
